Product Overview
[Drug Name]
Generic Name: Lansoprazole Enteric-Coated Tablets
Trade Name: LanWeiShu Lansoprazole Enteric-Coated Tablets 30mg*7 Tablets
Pinyin Code: LanWeiShu LanSuoLaZuoChangRongPian 30mg*7 Tablets
[Main Ingredients]
The main ingredient of this product is lansoprazole.
[Properties]
This product is a white enteric-coated tablet that appears white or off-white after removal of the enteric coating.
[Indications/Main Functions]
Gastric ulcer, duodenal ulcer, reflux disease, Zollinger-Ellison syndrome (gastrinoma), and anastomotic ulcers.
[Specifications]
30mg*7 tablets
[Dosage and Administration]
For duodenal ulcers, adults should take 30mg once daily for 4-6 weeks. For gastric ulcers, reflux esophagitis, Zollinger-Ellison syndrome (gastrinoma), and anastomotic ulcers, adults should take 30mg once daily for 6-8 weeks. For maintenance treatment, the dosage may be reduced for elderly patients and those with impaired liver and kidney function.
[Adverse Reactions]
1. Hypersensitivity: Occasionally, symptoms such as rash and itching may occur. Discontinue use if these symptoms occur. 2. Hematologic: Occasionally, symptoms such as anemia, leukopenia, and eosinophilia may occur. Thrombocytopenia is rare. 3. Digestive: Occasionally, symptoms such as constipation, diarrhea, thirst, and abdominal distension may occur. Elevated ALT, AST, ALP, LDH, and γ-GTP levels may occur. Careful observation is recommended. If any abnormalities occur, appropriate measures should be taken, including discontinuation of the drug. 4. Neuropsychiatric: Occasionally, symptoms such as headache and drowsiness may occur. Insomnia and dizziness may rarely occur. 5. Other: Occasionally, symptoms such as fever, elevated total cholesterol, and elevated uric acid may occur.
[Contraindications]
This product is contraindicated in patients with allergies.
[Drug Interactions]
This product may delay the metabolism and excretion of diazepam and phenytoin sodium.
[Precautions]
1. Observation is recommended during treatment. Due to insufficient experience with long-term use, this product is not currently recommended for maintenance therapy. 2. Do not chew this tablet; swallow it whole with water. 3. Use with caution in patients with liver dysfunction and the elderly. 4. This product may mask the symptoms of gastric cancer; therefore, it should only be used after the possibility of gastric cancer has been ruled out.
[Pediatric Use]
The safety of this product for pediatric use has not been established.
[Elderly Use]
Generally, elderly patients have decreased gastric acid secretion and other physiological functions, so close observation is recommended during treatment.
[Pharmacology and Toxicology]
This product is a benzimidazole compound. After oral absorption, it is translocated to the gastric mucosa and, under acidic conditions, converted into an active metabolite. This active metabolite specifically inhibits the H+/K+-ATPase system in gastric parietal cells, blocking the final step of gastric acid secretion. This product inhibits basal and stimulated gastric acid secretion in a dose-dependent manner. It does not antagonize cholinergic and amine H2 receptors.
